Orlistat: instructions, application

Therapeutic agents

Other lipid-lowering drugs

The nosological classification (ICD-10)

E66 Obesity

Pharmacology

Orlistat. Application: According to Physician Desk Reference (2009), orlistat is indicated for the treatment of obesity, including reduce and maintain body weight, in conjunction with a hypocaloric diet.

Orlistat. Application: According to Physician Desk Reference (2009), orlistat is indicated for the treatment of obesity, including reduce and maintain body weight, in conjunction with a hypocaloric diet.

Mode of action — inhibits gastrointestinal lipases.

Application

The drug is indicated for the treatment of obesity, including reduce and maintain body weight, in conjunction with a hypocaloric diet. Orlistat is also used to reduce the risk of re weight gain after initial reduction. Orlistat is indicated for patients with obesity with a body mass index (BMI, its calculation — see «Special instructions».) ≥30 kg / m 2 or ≥27 kg / m2 in the presence of other risk factors (diabetes, hypertension, dyslipidemia).

Contraindications

Hypersensitivity, chronic malabsorption syndrome, cholestasis.

Restrictions apply

Children’s age (safety and efficacy not established), a history of hyperoxaluria, nephrolithiasis (calcium oxalate stones).

Pregnancy and breast-feeding

Adequate well-controlled studies of orlistat in pregnant women have been conducted. Since Data from animal tests cannot always predetermine the response in humans, orlistat is not recommended during pregnancy.

Category effects on the fetus by FDA — X.

It is not known whether orlistat is secreted into breast milk, it should not be used in lactating women.

Side effects

Flatulence, compelling urge to defecate, oily stool, increased defecation, fecal incontinence, and allergic reactions. Contraindications: hypersensitivity, chronic malabsorption syndrome, cholestasis, pregnancy, breast-feeding (at the reception), children’s age (the application has not been studied). more frequent bowel movements, oily discharge from the rectum, fatty stools, gas evolution with a certain amount of discharge, urgency to defecate, fecal incontinence.

Pharmacological action: inhibiting intestinal lipase, lipid-lowering. Blocks splitting triglycerides in the gut reduces the absorption of free fatty acids and monoglycerides in limiting calorie intake and reduces body weight. Almost not absorbed into the systemic circulation. Write mainly in faeces (97%), including: 83% unchanged; Only 2% — excreted by the kidneys. The concentration of fat in the feces increased in 24-48 hours after a single dose and returned to baseline within 48-72 hours. complete elimination time is 3-5 days. Not accumulates. Reduces body weight, visceral fat depot, thereby reducing blood cholesterol and triglyceride levels, improved glucose tolerance, non-insulin dependent diabetes mellitus compensation, reduces blood pressure. Indications: obesity. Contraindications: hypersensitivity, chronic malabsorption syndrome, cholestasis, pregnancy, breast-feeding (at the reception), children’s age (the application has not been studied). more frequent bowel movements, oily discharge from the rectum, fatty stools, gas evolution with a certain amount of discharge, urgency to defecate, fecal incontinence.

Structure and Composition

1 capsule contains 120 mg of orlistat; in blister 21 pcs., in box 1 blister. Orlistat Structure and Composition: 1 capsule contains 120 mg of orlistat; in blister 21 pcs., in box 1 blister.